Actineer Inc. is a joint venture focused on the industrial scale production of Actinium-225, a medical isotope used in targeted alpha therapy for cancer treatment.

Actineer

Actineer, Inc. | 447 followers on LinkedIn. Actineer™ Inc. is a joint venture company between Canadian Nuclear Laboratories (CNL) and ITM Isotope Technologies Munich SE (ITM) dedicated to advancing Ac-225 technologies, quickly securing supply, and producing industrial-scale quantities of this valuable, rare medical radioisotope for the treatment of cancer.  Founded in October 2023, Actineer™ Inc. together with its strong supply chain collaborators will progress Ac-225 development, production and processing technologies to establish short-term production capabilities that will significantly boost international supplies, while working long-term towards the construction of a new Actinium Production Facility (APF) in Canada. The joint venture’s mission is to fulfil the unmet global manufacturing and production needs of this coveted radioisotope with significant potential in the fight against cancer.

Director Business and Operations - Actineer Inc.

Dr. Andreas Benischke

Actineer, Inc.

Actineer Advances Actinium-225 Production! We are proud to announce that Actineer, the joint venture between ITM Isotope Technologies Munich SE and Canadian Nuclear Laboratories (CNL), has successfully completed the cyclotron irradiation of Radium-226 (Ra-226), marking a significant step forward in the production of #Actinium -225 ( #Ac -225). An important achievement to support the development of #TargetedAlphaTherapy ( #TAT ) and provide cancer patients with new treatment options. For more details, check out our announcement: https://lnkd.in/dgB9_YSX

Exciting News! 🚀 Our new corporate website is LIVE! ✨ Check out www.actineer.com and explore the potential of Actinium-225 for next-generation #radiopharmaceuticals in cancer treatment. This new website provides valuable information about Actinium-225 as a medical radioisotope and the unique synergy between Canadian Nuclear Laboratories and ITM Isotope Technologies Munich SE in building this joint venture with its cross-functional supply chain from manufacturing to sales & distribution. #WebsiteLaunch #Actinium

Learn more about #Actinium225 as a potential weapon in the fight against cancer at the #webinar hosted by the Canadian Nuclear Isotope Council and 𝗔𝗰𝘁𝗶𝗻𝗲𝗲𝗿 on April 11, 2024. 💡 The hour-long event will highlight how industry is revolutionizing the production of emerging medical #isotopes like Ac-225, how Canadian Nuclear Laboratories and ITM Isotope Technologies Munich SE 's new joint venture Actineer, Inc. is working to produce Ac-225 at a commercial scale, and how Ac-225 and Targeted Alpha Therapy (TAT) offers significant benefits to cancer patients. ⚕️ Moderated by 𝗔𝗻𝗱𝗿𝗲𝘄 𝗧𝗵𝗶𝗲𝗹𝗲 , Executive Director of Canadian Nuclear Isotope Council, the webinar will platform: 👉 Carolina Aguiar Ferreira - Assistant Professor of Radiology, Pharmacology & Toxicology and Biomedical Engineering at Michigan State University 👉 Mike Sathekge - Head of Nuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, South Africa 👉 Ram Mullur - President of Actineer, Inc. To register for this webinar please click the button below. #radiopharmaceuticals #PrecisionOncology

We are proud to be a member of the Canadian Nuclear Isotope Council and are looking forward to this collaboration. Read the full press release here: https://lnkd.in/gTAJ4e5Z #actinium #radiopharma #radiopharmaceutical #oncology

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 12, 2024 9:14 AM	8e6a993e
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 12, 2024 9:14 AM	1fb298ad
crunchbase trigger	general	Nov 12, 2024 9:14 AM	a75632b6
crunchbase profile	general
li profile	general	Nov 12, 2024 9:14 AM	32add8a3
translate crunchbase fundingrounds	general
peers	general	Nov 12, 2024 9:14 AM	2243c38e
news basic	general	Nov 12, 2024 9:14 AM	f8dcdcbb
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

ACTI

COM:ACTINEER

Actineer